European Commission grants approval to Sandoz’s biosimilar to treat retinal diseases

Sandoz has received marketing authorization for its biosimilar Afqlir, a treatment for retinal diseases including nAMD, from the European Commission. The launch is expected in Q4 2025 and is a key driver for the company’s growth strategy. Chief Scientific Officer Claire D’Abreu-Hayling highlighted the importance of affordable and effective treatments for patients affected by nAMD.